New research suggests that patients who stop using popular GLP-1 drugs like Wegovy and Mounjaro may regain reduced body mass much more quickly than those who end conventional diet and exercise programs.
Published data in a leading health publication points out that while overweight individuals frequently drop a large proportion of their body weight while using the jabs, the mass is regained at an estimated rate of 0.8 kg per month after stopping.
"Individuals purchasing these treatments must be aware of the risk of quick rebound weight gain when the therapy is stopped," cautioned lead investigator Dr. Susan Jebb.
This pace of recovery suggests a return to starting weight within about a year and a half.
Analyzing Approaches
The analysis, which examined dozens of studies involving over 9,000 of participants, contrasted the effects of these new drugs with older methods.
Scientists emphasize that people who lose weight through dieting typically see a slower creep back—approximately 0.1 kg a month—post-intervention.
Understanding the Fast Regain
Nutrition scientists suggest the mode of action of the injections explains the accelerated rebound.
The injections mimic a natural hormone called GLP-1, which moderates appetite.
"Sustained high doses of GLP-1 levels far above than the body's typical production could lead to the body to produce less of its own natural hormone, and could diminish sensitivity to its effects," said Dr. Adam Collins, a nutrition expert.
"Discontinuation of this medication results in hunger is unsuppressed, making excessive eating much more probable."
An Ongoing Issue?
Health authorities suggest the injections for individuals with weight-linked medical conditions, accompanied by recommended lifestyle changes.
Professionals argue that, due to the likelihood of relapse, the therapy should be considered life-long.
This view is supported by pharmaceutical companies, who say that the results "emphasize the persistent nature of obesity," comparing it to managing diseases like diabetes.
User Accounts
Individuals who have come off the jabs explain a powerful resurgence of appetite.
"It was like something activating and I was suddenly extremely hungry," recalled one woman.
This challenge is worsened if users have not established sustainable lifestyle or habit changes during treatment.
Significant Use
Figures show that a significant number of adults in the UK have used these injections in the last 12 months, with interest continuing to grow.
- Adoption is higher among women than men.
- The 40s and 50s age group shows the greatest level of interest.
- Many obtain the medications through private prescriptions rather than the NHS.
Finally, researchers caution that while the jabs are effective agents for weight loss, they are not a magic solution and maintained weight loss likely depends on integrated behavioural support.
